FY2025 Earnings Estimate for CRSP Issued By Leerink Partnrs

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings per share estimates for CRISPR Therapeutics in a report released on Monday, November 10th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($5.09) per share for the year, up from their prior estimate of ($5.38). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($1.07) EPS, FY2026 earnings at ($5.18) EPS and FY2027 earnings at ($5.17) EPS.

A number of other analysts also recently issued reports on the company. Zacks Research raised CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. JPMorgan Chase & Co. initiated coverage on CRISPR Therapeutics in a report on Thursday, September 18th. They set an “overweight” rating and a $70.00 price objective for the company. Needham & Company LLC reduced their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating for the company in a research note on Monday. Wedbush cut their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, November 5th. Finally, Robert W. Baird reduced their target price on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $67.84.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP traded down $1.06 during midday trading on Thursday, reaching $51.13. 391,451 shares of the company’s stock were exchanged, compared to its average volume of 2,549,014. The company’s 50 day simple moving average is $63.02 and its two-hundred day simple moving average is $53.44. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $78.48. The firm has a market capitalization of $4.87 billion, a PE ratio of -9.17 and a beta of 1.89.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 56,213 shares of company stock worth $3,810,458 in the last quarter. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Swiss National Bank grew its position in shares of CRISPR Therapeutics by 1.7% in the third quarter. Swiss National Bank now owns 159,100 shares of the company’s stock valued at $10,311,000 after purchasing an additional 2,700 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at $2,724,000. Rathbones Group PLC bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at about $201,000. SR One Capital Management LP increased its stake in shares of CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after buying an additional 989,812 shares during the period. Finally, Arete Wealth Advisors LLC increased its stake in shares of CRISPR Therapeutics by 28.7% in the 3rd quarter. Arete Wealth Advisors LLC now owns 7,370 shares of the company’s stock worth $478,000 after acquiring an additional 1,642 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.